Apollo introduces Cellvizio Technology
Posted on Mar 27 2014 | IBNS
Kolkata, Mar 26 : Apollo Gleneagles Institute of Gastroenterology has launched "Cellvizio Technology" for the first time in India.
Cellvizio, which is a product of Mauna Kea Technologies , is a probe-based Confocal Laser Endomicroscopy (pCLE) system that provides physicians and researchers high-resolution cellular views of tissue inside the body.
With Cellvizio, a microscope is threaded through an endoscope to enable physicians to see real-time what normally is seen under a microscope.
The Cellvizio Technology was launched by Mahesh Goenka, Director, Apollo Institute of Gastroenterology and the first doctor in the country to use the technology.
Rupali Basu, CEO, Apollo Gleneagles Hospitals and Eastern Region, Apollo Hospitals, India was also present on the occasion.
Speaking on the occasion, Mahesh Goenka, Director, Apollo Gleneagles Institute of Gastroenterology said, "This is great news for our patients. Optical biopsy with Cellvizio can now be used for improved patient management in several key gastroenterological indications and I am proud to be the first doctor in the country to provide such advanced care".
Rupali Basu, CEO, Apollo Gleneagles Hospitals, said, "The addition of Cellvizio is a great example of how we continue to break new grounds in India. An endoscopy is a technique which is an integral part of medical treatment. Cellvizio is a step to advance this technology further. Endoscopy is very vital to detecting a disease or condition deep within the body and the subsequent treatment depends on the outcome of this procedure."
She said: "However, before the introduction of Cellvizio, a truly microscopic view of the inner body may not have been possible in most cases. Since Cellvizio combines both endoscopy and microscopy, the outcome is certainly more accurate and definitive. Also, patients want their physicians to be able to diagnose or rule out a problem during an examination and then treat the problem as fast as possible without the need to come back for a separate procedure. This was not possible earlier in the absence of Cellvizio."